These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16455513)

  • 1. [Monoclonal antibodies for lymphomas and leukemias in 2005].
    Peffault de Latour R; Robin M; Bay JO
    Bull Cancer; 2006 Jan; 93(1):107-18. PubMed ID: 16455513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody studies in B(non-T)-cell malignancies.
    Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
    Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-targeted therapy for myeloid leukemia.
    Appelbaum FR
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal antibodies in the treatment of lymphoma].
    Mounier N; Gisselbrecht C
    Rev Prat; 2002 May; 52(9):982-5. PubMed ID: 12063765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
    Countouriotis A; Moore TB; Sakamoto KM
    Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation against leukemias and lymphomas: a realistic future treatment?
    Mittal S; Marshall NA; Barker RN; Vickers MA
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):101-8. PubMed ID: 17719232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
    Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapies in leukemias.
    Tallman MS
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):12-9. PubMed ID: 12447847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
    Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
    Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy in malignant lymphoma.
    Coiffier B
    Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant lymphomas].
    Yamaguchi Y; Usui N
    Gan To Kagaku Ryoho; 2009 May; 36(5):736-41. PubMed ID: 19461173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.